



NDA 20972/S-038  
NDA 21360/S-026

**SUPPLEMENT APPROVAL**

Bristol-Myers Squibb Company  
Attention: Hwei-Gene Wang, Ph.D.  
Associate Director, Global Regulatory Sciences, US  
5 Research Parkway, Room 215U, Mailstop 2AW-708  
Wallingford, CT 06492

Dear Dr. Wang:

Please refer to your Supplemental New Drug Applications (sNDA) received March 31, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Sustiva (efavirenz) Capsules, 50 mg, 200 mg and Sustiva (efavirenz) Tablets, 300 mg, 600 mg.

We acknowledge receipt of your amendments dated: May 12, 2011, August 12, 2011, September 08, 2011, and September 15, 2011.

These “Prior Approval” supplemental new drug applications provide the following revisions to the package inserts:

- Move the “Antiretroviral Pregnancy Registry” subsection from the “Warnings and Precautions, Reproductive Risk Potential” subsection to the “Use in Specific Populations, Pregnancy” subsection
- Update the “Antiretroviral Pregnancy Registry” subsection
- Add new drug interaction information regarding bupropion to the Drug Interactions and Clinical Pharmacology sections
- Update the Nonclinical Toxicology, Carcinogenesis, Mutagenesis and Impairment of Fertility subsections

In addition, the following revision was made to the patient package inserts:

- Bupropion was added to the list of drugs that may interact with Sustiva

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content

of labeling must be identical to the package insert and patient package insert enclosed, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Sohail Mosaddegh, Pharm.D., regulatory project manager, at (301) 796-4876 or 301-796-1500.

Sincerely yours,

*{See appended electronic signature page}*

Debra Birnkrant, M.D.  
Director  
Division of Antiviral Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

ENCLOSURE(S):  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

KENDALL A MARCUS  
09/26/2011